Format

Send to

Choose Destination
World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Author information

1
Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.
2
Center for Cancer Research, National Cancer Institute, NIH Maryland, Bethesda, USA.
3
Guy's and St, Thomas' Hospital, Great Maze Pond, London, UK.
4
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
5
Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
6
Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
7
Yale Cancer Center, New Haven, CT, USA.
8
Barts Cancer Institute, London, USA.
9
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
10
Memorial Sloan Kettering Cancer Center, New York, USA.
11
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
12
Department of Medical Oncology, Bladder Cancer Center, Dana Farber Cancer Institute, Boston, MA, USA.
13
Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. cnsternberg@corasternberg.com.

Abstract

The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

KEYWORDS:

Bladder cancer; Checkpoint inhibitors; Chemotherapy immunotherapy; Urothelial cancer

PMID:
30238401
DOI:
10.1007/s00345-018-2486-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center